AUROPHARMA Aurobindo Pharma Ltd Disruption of operations due to natural disasters, accidents, or other events Announcement 2023 - Product Updates Aurobindo Pharmas subsidiary, CuraTeQ Biologics, announces positive results in phase 3 clinical trial for its proposed Trastuzumab Biosimilar product..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Aurobindo Pharma Ltd